본문 바로가기
KERD
논문KCI 등재

새로운 항진균제와 임상적 적용

New Systemic Antifungal Agents and Clinical Applicationsi

백경란
대한의진균학회 (The Korean Society for Medical Mycology)|2005.12|대한의진균학회지 (Journal of Mycology and Infection)|제10권 제4호|pp. 135-143

1

조회

0

다운로드

1

인용

0

참고문헌

주제분류미생물학

초록

Abstract

Current antifungal agents, such as amphotericin B, fluconazole and itraconazole, have limitations in clinical use because of toxicity, low efficacy, and drug resistance. Newer systemic antifungal agents are available for better efficacy and lower toxicity. They include antifungal agents of a new class and a new generation of an existing class. Caspofungin, the first available echinocandin, inhibits cell wall synthesis and has broad antifungal spectrums. Caspofungin shows better antifungal activity against fluconazole¬resistant Candida and Aspergillus. Caspofungin was very effective in salvage therapy for amphotericin¬refractory or intolerant aspergillosis. Voriconazole, the first available second-generation triazole, is a derivative of fluconazole. Voriconazole is more active against Aspergillus than other antifungal agents and shows lower MIC (minimal inhibitory concentrations) against Candida. The clinical efficacy of voriconazole in the treatment of invasive aspergillosis is superior to amphotericin B. Voriconazole has some limitations, including visual adverse events, liver enzyme elevation as well as a number of drug interactions. Caspofungin and voriconazole should be judiciously used in clinical practices based on clinical efficacy, adverse events, and costs.

참고문헌 (38)

  1. "systematic review of the literature", 32(3), pp.358~366
  2. "A prospective and retrospective analysis of the nephrotoxicity and efficacy of lipid-based amphotericin B formulations", 21(9), pp.1107~1114 (2001)
  3. "Ampho- tericin B lipid complex for invasive fungal infec- tions analysis of safety and efficacy in 556 cases", 26(6), pp.1383~1396
  4. "Clinical experience with itraconazole in systemic fungal infections", 61(1), pp.39~47 (2001)
  5. "New antifungal agents", 21(3), pp.565~576 (2003)
  6. "Compounds active against cell walls of medically important fungi", 6(1), pp.1~21 (1993)
  7. "Echinocandin antifungal drugs", 362(9390), pp.1142~1151 (2003)
  8. "the first representative of a new antifungal class", 5(3), pp.513~521
  9. "In vitro activity of a new pneumocandin antifungal", 41(7), pp.1612 743~872 1614
  10. "In vitro susceptibility testing methods for caspofungin against Aspergillus and Fusarium isolates", 45(1), pp.327~330 (2001)
  11. "In vitro activity of two echinocandin derivatives against clinical isolates of Aspergillus", 30(4), pp.251~0991 743 255
  12. "Efficacy of caspofungin alone and in combination with voriconazole in a Guinea pig model of invasive aspergillosis", 46(8), pp.2564~2568 (2002)
  13. "Clinical pharmacology of antifungal compounds", 17(1), pp.159~191
  14. "a review of its use in oesophageal candidiasis", 63(20), pp.2235~2263
  15. "A ran- domized double-blind study of caspofungin versus amphotericin for the treatment of candidal esopha- gitis", 33(9), pp.1529~1535 (2001)
  16. "A ran- domized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candi- diasis", 113(4), pp.294~299 (2002)
  17. "Echinocandins--an advance in the primary treatment of invasive candidiasis", 347(25), pp.2070~2072 (2002)
  18. "Caspo- fungin versus liposomal amphotericin B for empi- rical antifungal therapy in patients with persistent fever and neutropenia", 351(14), pp.1391~1402 (2004)
  19. "Micafungin", 38(10), pp.1707~1721 (2004)
  20. "blocks sterol biosynthesis in Candida albicans and Candida krusei", 41(11), pp.2492~2496
  21. "In vitro antifungal activities of voriconazole and reference agents as determined by NCCLS methods review of the literature", 150(3), pp.101~115
  22. "Antifungal activity of voriconazole fluconazole and amphotericin B against hematoge- nous Candida krusei infection in neutropenic guinea pig model", 11(1), pp.34~39
  23. "A comparative study of fungicidal activities of vori- conazole and amphotericin B against hyphae of Aspergillus fumigatus", 55(6), pp.914~920 (2005)
  24. "Efficacy of voriconazole in a guinea pig model of disseminated invasive asper- gillosis", 44(10), pp.2865~2868 (2000)
  25. "In vitro susceptibilities of zygomycetes to conventional and new antifungals", 51(1), pp.45~52 (2003)
  26. "Pharmacokinetics of voriconazole in the cerebrospinal fluid of an immunocompromised pa- tient with a brain abscess due to Aspergillus fumi- gatus", 39(4), pp.603~604 (2004)
  27. "Effect of food on the pharmacokinetics of multiple-dose oral voriconazole", 56(1), pp.17~23 (2003)
  28. "Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens", 46(8), pp.2546~2553 (2002)
  29. "Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis", 347(6), pp.408~415 (2002)
  30. "multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients", 33(9), pp.1447~1454
  31. "Treatment of fluconazole-resistant candidiasis with voriconazole in patients with AIDS", 12(16), pp.2227~2228 (1998)
  32. "In vitro acti- vities of voriconazole and itraconazole against 566 clinical isolates of Cryptococcus neofor- mans from the United States and Africa", 43(1), pp.169~171
  33. "Development of azole resistance during fluconazole maintenance therapy for AIDS-associated cryptococcal disease", 15(17), pp.2344~2345 (2001)
  34. "Voriconazole compared with liposomal amphotericin B for empi- rical antifungal therapy in patients with neutropenia and persistent fever", 346(4), pp.225~234 (2002)
  35. "In vivo activity of posaconazole against Mucor spp in an immunosuppressed-mouse model", 46(7), pp.2310~2312
  36. "Antifungal activity and pharmacokinetics of posaconazole in treatment and prevention of experimental invasive pulmonary aspergillosis correlation with galactomannan antigenemia", 45(3), pp.857~869
  37. "Activities of caspofungin and ampho- tericin B against 448 recent clinical isolates of fila- mentous fungi", 41(8), pp.3623~3626
  38. "In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6 970 clinical iso- lates of Candida spp", 46(6), pp.1723~1727

관련 논문AI추천

소아에서 새로운 항진균제 요법박수은대한소아감염학회 · Pediatric Infection and Vaccine2006 · 제13권 제1호새로운 항진균제의 국내 사용 및 전망강문원, 김상일대한감염학회 · Infection and Chemotherapy2010 · 제42권 제4호전신성 항진균제와 임상적 이용류지소, 우준희, 전재범, 최상호대한의진균학회 · 대한의진균학회지2005 · 제10권 제1호주요 효모균과 사상형 진균의 항진균제 내성현황신종희대한감염학회 · Infection and Chemotherapy2009 · 제41권 제2호침습성 아스페르길루스증의 발생 양상과 치료결과강철인, 김성한, 김홍빈, 박상원, 박완범, 오명돈, 이기덕, 최강원, 최영주대한감염학회 · Infection and Chemotherapy2002 · 제34권 제3호국내 혈액질환 환자에서 침습성 진균 감염의 구제치료로서 Caspofungin의 효과와 안전성김춘추, 민우성, 박선희, 신완식, 유진홍, 이동건, 최수미, 최정현대한감염학회 · Infection and Chemotherapy2005 · 제37권 제5호

이 간행물의 다른 논문 (5건)

소와 각질융해증 환자에서 Benzoyl Peroxide와 Clindamycin Phosphate의 치료 효과에 관한 비교 연구이종희, 안지영, 권오상, 윤상웅, 조소연, 김명남, 원종현, 김수홍, 박경운, 김범준, 허창훈, 노낙경, 노병인, 김지영pp. 144-150동물접촉에 의한 피부 진균증의 임상 및 진균학적 고찰이양원, 임상희, 최용범, 안규중, 임선미pp. 151-159Trichophyton tonsurans에 의한 미만성 흑점 두부 백선 1예이동경, 이해웅, 고재경, 최지호, 장성은, 이미우, 문기찬pp. 160-165폐암 말기 환자에서 발생한 Phialemonium dimorphosporum과 Myrothecium Species에 의한 심재성 피부 진균증 1예최종수, 박소현, 김기홍, 신동훈, 신영민, 배영경pp. 166-172전박부에 비전형적으로 발생한 신생아성 피부칸디다증 1예서무규, 임재우, 이용환, 하경임pp. 173-176
원문 보기